The Indemnity Calculus For Covid-19 Vaccines, India’s Path Ahead

 
• By Anju Ghangurde

Legal experts discuss the intricacies around pharma’s demand for indemnity, a key sticking point for supplies of COVID-19 vaccines from Pfizer and Moderna, and the path forward for countries like India.

indemnity
To Indemnify Or Not, That Is the Question • Source: Alamy

More from Legal & IP

More from Pink Sheet